(Q35143063)

6 August 2017

title

The treatment of atopic dermatitis with topical immunomodulators (English)

1 reference

6 August 2017

1 reference

Nordwig S Tomi

1

1 reference

6 August 2017

Thomas A Luger

series ordinal

2

1 reference

6 August 2017

publication date

1 May 2003

1 reference

6 August 2017

published in

Clinics in Dermatology

1 reference

6 August 2017

volume

21

1 reference

6 August 2017

issue

3

1 reference

6 August 2017

page(s)

215-224

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2802%2900367-X

6 August 2017

1 reference

7 January 2021

Characterization of the mononuclear cell infiltrate in atopic dermatitis using monoclonal antibodies

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2802%2900367-X

7 January 2021

Induction of Fc epsilon R2/CD23 on human epidermal Langerhans cells by human recombinant interleukin 4 and gamma interferon

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2802%2900367-X

7 January 2021

Immunomorphological and ultrastructural characterization of Langerhans cells and a novel, inflammatory dendritic epidermal cell (IDEC) population in lesional skin of atopic eczema

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2802%2900367-X

7 January 2021

Dermal deposition of eosinophil-granule major basic protein in atopic dermatitis. Comparison with onchocerciasis

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2802%2900367-X

7 January 2021

Mast cells and atopic dermatitis. Stereological quantification of mast cells in atopic dermatitis and normal human skin

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2802%2900367-X

7 January 2021

High-expression of sphingomyelin deacylase is an important determinant of ceramide deficiency leading to barrier disruption in atopic dermatitis

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2802%2900367-X

7 January 2021

Biphasic response against aeroallergen in atopic dermatitis showing a switch from an initial TH2 response to a TH1 response in situ: an immunocytochemical study

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2802%2900367-X

7 January 2021

T cells in atopic dermatitis

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2802%2900367-X

7 January 2021

Autoantibodies in atopic dermatitis

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2802%2900367-X

7 January 2021

Autoallergy: a pathogenetic factor in atopic dermatitis?

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2802%2900367-X

7 January 2021

Molecular characterization of an autoallergen, Hom s 1, identified by serum IgE from atopic dermatitis patients

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2802%2900367-X

7 January 2021

Atopy: immunodeviation and environment

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2802%2900367-X

7 January 2021

Cytokine network and dysregulated apoptosis in atopic dermatitis

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2802%2900367-X

7 January 2021

No eczema without keratinocyte death

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2802%2900367-X

7 January 2021

Ocular complications of topical, peri-ocular, and systemic corticosteroids

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2802%2900367-X

7 January 2021

Cataracts, glaucoma, and femoral avascular necrosis caused by topical corticosteroid ointment

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2802%2900367-X

7 January 2021

Efficacy versus systemic effects of six topical steroids in the treatment of atopic dermatitis of childhood

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2802%2900367-X

7 January 2021

Successful treatment of resistant facial lesions of atopic dermatitis with 0.1% FK506 ointment

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2802%2900367-X

7 January 2021

Leflunomide and methotrexate

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2802%2900367-X

7 January 2021

Mycophenolate mofetil in autoimmune and inflammatory skin disorders

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2802%2900367-X

7 January 2021

Cyclosporin ointment for psoriasis and atopic dermatitis

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2802%2900367-X

7 January 2021

Topical tacrolimus (FK 506): a new milestone in the management of atopic dermatitis

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2802%2900367-X

7 January 2021

Tacrolimus: a new topical immunomodulatory therapy for atopic dermatitis.

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2802%2900367-X

7 January 2021

The immunosuppressant FK-506 specifically inhibits mitogen-induced activation of the interleukin-2 promoter and the isolated enhancer elements NFIL-2A and NF-AT1

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2802%2900367-X

7 January 2021

Pimecrolimus (Elidel, SDZ ASM 981)--preclinical pharmacologic profile and skin selectivity

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2802%2900367-X

7 January 2021

FK506 in the treatment of inflammatory skin disease: promises and perspectives.

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2802%2900367-X

7 January 2021

Effects of cyclosporin A and FK506 on Fc epsilon receptor type I-initiated increases in cytokine mRNA in mouse bone marrow-derived progenitor mast cells: resistance to FK506 is associated with a deficiency in FK506-binding protein FKBP12

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2802%2900367-X

7 January 2021

Topical tacrolimus (FK506) leads to profound phenotypic and functional alterations of epidermal antigen-presenting dendritic cells in atopic dermatitis

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2802%2900367-X

7 January 2021

Fc epsilon RI-expressing antigen-presenting cells: new players in the atopic game

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2802%2900367-X

7 January 2021

Lesional expression of interferon-gamma in atopic eczema

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2802%2900367-X

7 January 2021

A novel anti-inflammatory drug, SDZ ASM 981, for the treatment of skin diseases: in vitro pharmacology

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2802%2900367-X

7 January 2021

Ascomycins: promising agents for the treatment of inflammatory skin diseases

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2802%2900367-X

7 January 2021

High Frequency of IL-4–Producing CD4+ Allergen-Specific T Lymphocytes in Atopic Dermatitis Lesional Skin

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2802%2900367-X

7 January 2021

The ascomycin macrolactam pimecrolimus (Elidel, SDZ ASM 981) is a potent inhibitor of mediator release from human dermal mast cells and peripheral blood basophils

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2802%2900367-X

7 January 2021

Ascomycin macrolactam derivative SDZ ASM 981 inhibits the release of granule-associated mediators and of newly synthesized cytokines in RBL 2H3 mast cells in an immunophilin-dependent manner

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2802%2900367-X

7 January 2021

Atopic dermatitis-like symptoms in hypomagnesaemic hairless rats are prevented and inhibited by systemic or topical SDZ ASM 981

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2802%2900367-X

7 January 2021

Possible inhibitory mechanism of FK506 (tacrolimus hydrate) ointment for atopic dermatitis based on animal models

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2802%2900367-X

7 January 2021

Inhibition of contact allergy reactions by topical FK506.

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2802%2900367-X

7 January 2021

Tacrolimus ointment does not affect collagen synthesis: results of a single-center randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2802%2900367-X

7 January 2021

The new topical ascomycin derivative SDZ ASM 981 does not induce skin atrophy when applied to normal skin for 4 weeks: a randomized, double-blind controlled study

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2802%2900367-X

7 January 2021

The impact of tacrolimus ointment on health-related quality of life of adult and pediatric patients with atopic dermatitis

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2802%2900367-X

7 January 2021

Long-term efficacy of tacrolimus ointment for recalcitrant facial erythema resistant to topical corticosteroids in adult patients with atopic dermatitis.

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2802%2900367-X

7 January 2021

Safety and efficacy of 1 year of tacrolimus ointment monotherapy in adults with atopic dermatitis. The European Tacrolimus Ointment Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2802%2900367-X

7 January 2021

Tacrolimus (FK506) ointment for atopic dermatitis: a phase I study in adults and children

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2802%2900367-X

7 January 2021

A short-term trial of tacrolimus ointment for atopic dermatitis. European Tacrolimus Multicenter Atopic Dermatitis Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2802%2900367-X

7 January 2021

Long-term safety and efficacy of tacrolimus ointment for the treatment of atopic dermatitis in children

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2802%2900367-X

7 January 2021

A 12-week study of tacrolimus ointment for the treatment of atopic dermatitis in pediatric patients

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2802%2900367-X

7 January 2021

A randomized, vehicle-controlled trial of tacrolimus ointment for treatment of atopic dermatitis in children. Pediatric Tacrolimus Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2802%2900367-X

7 January 2021

Tacrolimus ointment in the treatment of chronic cutaneous graft-vs-host disease: a case series of 18 patients

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2802%2900367-X

7 January 2021

Tacrolimus ointment for the treatment of steroid-induced rosacea: a preliminary report

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2802%2900367-X

7 January 2021

An open study of a lotion formulation to improve tolerance of tacrolimus in facial atopic dermatitis

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2802%2900367-X

7 January 2021

Tacrolimus ointment for the treatment of atopic dermatitis in adult patients: part II, safety.

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2802%2900367-X

7 January 2021

The eczema area and severity index (EASI): assessment of reliability in atopic dermatitis.

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2802%2900367-X

7 January 2021

Tacrolimus ointment for the treatment of atopic dermatitis in adult patients: part I, efficacy

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2802%2900367-X

7 January 2021

Tacrolimus concentrations in blood during topical treatment of atopic dermatitis

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2802%2900367-X

7 January 2021

Tacrolimus ointment for atopic dermatitis

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2802%2900367-X

7 January 2021

Tacrolimus: a further update of its pharmacology and therapeutic use in the management of organ transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2802%2900367-X

7 January 2021

Tacrolimus: a review of its use for the management of dermatoses

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2802%2900367-X

7 January 2021

Tacrolimus ointment reduces staphylococcal colonization of atopic dermatitis lesions

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2802%2900367-X

7 January 2021

FK-506, a novel immunosuppressant isolated from a Streptomyces. I. Fermentation, isolation, and physico-chemical and biological characteristics

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2802%2900367-X

7 January 2021

FK-506, a novel immunosuppressant isolated from a Streptomyces. II. Immunosuppressive effect of FK-506 in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2802%2900367-X

7 January 2021

Clinical risk factors associated with nonmelanoma skin cancer in renal transplant recipients.

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2802%2900367-X

7 January 2021

Are viral warts seen more commonly in children with eczema?

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2802%2900367-X

7 January 2021

Effectiveness of the ascomycin macrolactam SDZ ASM 981 in the topical treatment of atopic dermatitis

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2802%2900367-X

7 January 2021

SDZ ASM 981: an emerging safe and effective treatment for atopic dermatitis

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2802%2900367-X

7 January 2021

Long-term management of atopic dermatitis in infants with topical pimecrolimus, a nonsteroid anti-inflammatory drug.

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2802%2900367-X

7 January 2021

Efficacy and safety of pimecrolimus cream in the long-term management of atopic dermatitis in children

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2802%2900367-X

7 January 2021

First experience of topical SDZ ASM 981 in children with atopic dermatitis

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2802%2900367-X

7 January 2021

10.1016/S0738-081X(02)00367-X

Identifiers

DOI

1 reference

6 August 2017

1 reference